MalDA, Accelerating Malaria Drug Discovery
Author(s)
Yang, Tuo; Ottilie, Sabine; Istvan, Eva S; Godinez-Macias, Karla P; Lukens, Amanda K; Baragaña, Beatriz; Campo, Brice; Walpole, Chris; Niles, Jacquin C; Chibale, Kelly; Dechering, Koen J; Llinás, Manuel; Lee, Marcus CS; Kato, Nobutaka; Wyllie, Susan; McNamara, Case W; Gamo, Francisco Javier; Burrows, Jeremy; Fidock, David A; Goldberg, Daniel E; Gilbert, Ian H; Wirth, Dyann F; Winzeler, Elizabeth A; ... Show more Show less
DownloadPublished version (2.064Mb)
Publisher with Creative Commons License
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
© 2021 The Authors The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories. The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process by identifying new, essential, druggable targets. In addition, it seeks to produce early lead inhibitors that may be advanced into drug candidates suitable for preclinical development and subsequent clinical testing in humans. By sharing resources, including expertise, knowledge, materials, and reagents, the consortium strives to eliminate the structural barriers often encountered in the drug discovery process. Here we discuss the mission of the consortium and its scientific achievements, including the identification of new chemically and biologically validated targets, as well as future scientific directions.
Date issued
2021-02Department
Massachusetts Institute of Technology. Department of Biological EngineeringJournal
Trends in Parasitology
Publisher
Elsevier BV
ISSN
1471-5007